First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to see what effects the treatment regimen chemotherapy
(carboplatin and paclitaxel) plus immunotherapy (pembrolizumab), has on patients who have
been diagnosed with head/neck squamous cell carcinoma and are unable to take the drug
5-fluorouracil